Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123703 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL23123706 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL30155479 | 0.82 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL15725772 | 0.81 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL15244129 | 0.80 | SMN1; SMN2 (0.43) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL21871397 | 0.80 | HPGD (0.48) | HPGDRECQLEPHX1PIK3CAGPR119 | |
| SCHEMBL24424564 | 0.80 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL24424565 | 0.80 | CHRM2 (0.49) | CHRM2CHRM1CHRM3PREPHPGD | |
| SCHEMBL21871865 | 0.80 | HPGD (0.50) | HPGDRECQLEPHX1GPR119USP2 | |
| SCHEMBL1546995 | 0.80 | HPGD (0.50) | HPGDRECQLEPHX1GPR119USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | CHRM2 2286/4885CHRM1 1705/4885CHRM3 1891/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | CHRM2 2534/4885CHRM1 1920/4885CHRM3 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.